Palliative Benefits of the Multimodality Approach in the Re-treatment of Recurrent Malignant Glioma: Two Case Reports.
Two young male patients treated seven and four years back, for malignant glioma, returned with recurrence at the same site, with a World Health Organization (WHO) Performance Score of four and two. Both underwent resurgery and received postoperative reirradiation of 5040 cGy in 28 fractions and concurrent Temozolomide 75 mg/m(2) body surface area (BSA) daily, and one patient received additional adjuvant Temozolomide 250 mg (150 mg/m(2) BSA). Both patients tolerated the treatment well with 16 and 14 months follow-up from the time of recurrence. They were symptom-free, with normal physical function and good mental state, and resumed their respective jobs.
Tr
Arulponni
A
Department of Radiation Oncology, M.S. Ramaiah Medical Teaching Hospital, Bangalore - 560 054, India.
Mg
Janaki
J
S
Nirmala
N